Score Overview
Explore the 2021 public Archive ranking →
Where Cytokinetics Inc has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- CYTK
2015: 75.8% · 2021: 72.7% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-23 | $ 61.23 | — |
1 Year2025-10-23 | $ 57.50 | 6.49% |
5 Years2021-10-22 | $ 37.03 | 65.35% |
10 Years2016-10-21 | $ 9.19 | 6x |
20 Years2006-10-23 | $ 42.54 | 43.94% |
All Time2004-04-29 | $ 16.10 | 280.31% |
| Period | Last Price2026-10-23 | 1 Year2025-10-23 | 5 Years2021-10-22 | 10 Years2016-10-21 | 20 Years2006-10-23 | All Time2004-04-29 |
|---|---|---|---|---|---|---|
| Price | $ 61.23 | $ 57.50 | $ 37.03 | $ 9.19 | $ 42.54 | $ 16.10 |
| Return | — | 6.49% | 65.35% | 6x | 43.94% | 280.31% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 70M | -$ 894M | $ 1.16B |
| 2025 | $ 88M | -$ 784M | $ 882M |
| 2024 | $ 18M | -$ 589M | $ 1.07B |
| 2023 | $ 7M | -$ 526M | $ 614M |
| 2022 | $ 94M | -$ 388M | $ 782M |
| 2021 | $ 70M | -$ 215M | $ 471M |
| 2020 | $ 55M | -$ 127M | $ 464M |
| 2019 | $ 26M | -$ 121M | $ 225M |
| 2018 | $ 31M | -$ 106M | $ 198M |
| 2017 | $ 13M | -$ 127M | $ 268M |
| 2016 | $ 106M | $ 16M | $ 156M |
| 2015 | $ 28M | -$ 37M | $ 111M |
| 2014 | $ 46M | -$ 14M | $ 83M |
| 2013 | $ 30M | -$ 33M | $ 77M |
| 2012 | $ 7M | -$ 41M | $ 74M |
| 2011 | $ 4M | -$ 47M | $ 49M |
| 2010 | $ 2M | -$ 49M | $ 71M |
| 2009 | $ 81M | $ 24M | $ 114M |
| 2008 | $ 12M | -$ 56M | $ 56M |
| 2007 | $ 13M | -$ 48M | $ 119M |
| 2006 | $ 3M | -$ 57M | $ 109M |
| 2005 | $ 8M | -$ 42M | $ 76M |
| IPO2004 | $ 13M | -$ 37M | $ 105M |
Cytokinetics Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 55M to $ 88M and net income went from -$ 127M to -$ 784M. Revenue increased in 3 of those 5 years; net income in 0.
Between 2005 and 2025, revenue grew from $ 8M to $ 88M and net income went from -$ 42M to -$ 784M. Revenue increased in 13 of those 20 years; net income in 8.
Cytokinetics Inc currently holds a 20-year HDB Score of 2.7 out of 10. How the HDB Score is calculated.
Membership
Continue CYTK’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,112 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
